Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01294735 | Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1) | PHASE1 | COMPLETED | 19 | — | — | Feb 1, 2011 | May 1, 2012 | Aug 15, 2012 | - | — |
| Arm | Type | Description |
|---|---|---|
| Part A, MK-4827 + temozolomide dose escalation cohort | EXPERIMENTAL | - |
| Part B, MK-4827 + temozolomide melanoma cohort | EXPERIMENTAL | - |
| Part B, MK-4827 + temozolomide glioblastoma multiforme cohort | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MK-4827 | DRUG | MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme. |
| Temozolomide | DRUG | MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme. |
Inclusion criteria Part A * Participants with histologically-confirmed advanced solid tumors who have failed to respond to standard therapy, or progressed on standard therapy, or for whom standard therapy does not exist. Part B * Participants must have a histologically-confirmed recurrent gliobl...